“Through due diligence, investors and pharma companies take a closer look at their potential partner, the asset, and the deal itself to validate claims and evaluate risks. With many millions of dollars riding on the success of licensing and acquisition activities, a deal gone wrong can mean significant debt and …

"Inpart is the best platform we've ever worked with! We've been subscribed since the start of 2018, and have received a range of useful introductions and feedback for our technologies from relevant companies in Europe and beyond."